# QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct06951997/  
OnCo record `nct06951997` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of iparomlimab and tuvonralimab, tucidinostat (chidamide), gemcitabine and nab-paclitaxel in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.

## Summary

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT06951997 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 33 participants, started 2025-03-07 and due to reach its primary completion in 2027-05-15. Interventions recorded: QL1706; Chidamide; Gemcitabine; Nab-paclitaxel. Conditions listed: Metastatic Pancreatic Cancer. Primary outcome: ORR. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed diagnosis of pancreatic cancer (originating from the pancreatic ductal epithelium), with clinical records showing metastatic pancreatic cancer (stage IV according to the AJCC 8th edition TNM staging of pancreatic cancer)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06951997
- Phase: 2
- Setting: Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chidamide, Albumin-bound Paclitaxel and Gemcitabine as First-line Treatment for Metastatic Pancreatic Cancer
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT06951997: https://clinicaltrials.gov/study/NCT06951997

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Iparomlimab and tuvonralimab](https://onco.cc/drugs/iparomlimab-tuvonralimab/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Tucidinostat (chidamide)](https://onco.cc/drugs/tucidinostat/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06951997.json